Herrstedt J, Lindberg S, Petersen P
Drugs Aging. 2021; 39(1):1-21.
PMID: 34882284
PMC: 8654643.
DOI: 10.1007/s40266-021-00909-8.
Saikia B, Choudhury Barua C, Haloi P, Patowary P
Indian J Pharmacol. 2017; 49(1):42-48.
PMID: 28458421
PMC: 5351237.
DOI: 10.4103/0253-7613.201025.
Mitchelson F
Drugs. 2017; 43(4):443-463.
PMID: 28421555
DOI: 10.2165/00003495-199243040-00003.
Rock E, Limebeer C, Parker L
Exp Brain Res. 2014; 232(8):2511-34.
PMID: 24792499
DOI: 10.1007/s00221-014-3942-9.
Bois A
Med Klin (Munich). 2009; 93 Suppl 1:3-17.
PMID: 19479418
DOI: 10.1007/BF03041988.
The effects of gamma-radiation on intestinal motor activity and faecal pellet expulsion in the guinea pig.
Krantis A, Rana K, Harding R
Dig Dis Sci. 1996; 41(12):2307-16.
PMID: 9011434
DOI: 10.1007/BF02100119.
An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Sorbe B, Hallen C, Frankendal B
Cancer Chemother Pharmacol. 1994; 33(4):298-302.
PMID: 8281622
DOI: 10.1007/BF00685903.
The anti-emetic efficacy and tolerability of tropisetron in patients conditioned with high-dose chemotherapy (with and without total body irradiation) prior to bone marrow transplantation.
Or R, Drakos P, Nagler A, Naparstek E, Kapelushnik J, Cass Y
Support Care Cancer. 1994; 2(4):245-8.
PMID: 8087443
DOI: 10.1007/BF00365730.
Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic.
Lee C, Plosker G, McTavish D
Drugs. 1993; 46(5):925-43.
PMID: 7507039
DOI: 10.2165/00003495-199346050-00009.
Effect of ICS 205-930 (a specific 5-HT3 receptor antagonist) on gastric emptying of a solid meal in normal subjects.
Akkermans L, Vos A, Hoekstra A, Roelofs J, Horowitz M
Gut. 1988; 29(9):1249-52.
PMID: 3198000
PMC: 1434369.
DOI: 10.1136/gut.29.9.1249.
Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.
Cassidy J, Raina V, Lewis C, Adams L, Soukop M, Rapeport W
Br J Cancer. 1988; 58(5):651-3.
PMID: 2851312
PMC: 2246838.
DOI: 10.1038/bjc.1988.278.
The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.
Bermudez J, Boyle E, Miner W, Sanger G
Br J Cancer. 1988; 58(5):644-50.
PMID: 2851311
PMC: 2246836.
DOI: 10.1038/bjc.1988.277.
Effects of a 5-hydroxytryptamine3 receptor antagonist (ICS 205-930) on colonic motor activity in healthy men.
Stacher G, Gaupmann G, Schneider C, Abatzi T, Steinringer H
Br J Clin Pharmacol. 1989; 28(3):315-22.
PMID: 2789925
PMC: 1379950.
DOI: 10.1111/j.1365-2125.1989.tb05432.x.
A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response.
Carmichael J, Cantwell B, Edwards C, Zussman B, Thompson S, Rapeport W
Cancer Chemother Pharmacol. 1989; 24(1):45-9.
PMID: 2541937
DOI: 10.1007/BF00254104.
Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides.
Talley N, Phillips S, Haddad A, Miller L, Twomey C, Zinsmeister A
Dig Dis Sci. 1989; 34(10):1511-5.
PMID: 2529108
DOI: 10.1007/BF01537102.
Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors.
Hamik A, Peroutka S
Cancer Chemother Pharmacol. 1989; 24(5):307-10.
PMID: 2527092
DOI: 10.1007/BF00304763.
The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties.
Stott J, Barnes G, Wright R, Ruddock C
Br J Clin Pharmacol. 1989; 27(2):147-57.
PMID: 2523720
PMC: 1379774.
DOI: 10.1111/j.1365-2125.1989.tb05345.x.
Topographical distribution of 5-HT3 receptor recognition sites in the ferret brain stem.
Barnes J, Barnes N, Costall B, Naylor I, Naylor R, Rudd J
Naunyn Schmiedebergs Arch Pharmacol. 1990; 342(1):17-21.
PMID: 2402300
DOI: 10.1007/BF00178966.
Effects of the 5-HT3 receptor antagonist ICS 205-930 on fat-delayed gastric emptying and antral motor activity.
Stacher G, Bergmann H, Schneider C, Gaupmann G, Steinringer H, Abatzi T
Br J Clin Pharmacol. 1990; 30(1):41-8.
PMID: 2390431
PMC: 1368273.
DOI: 10.1111/j.1365-2125.1990.tb03741.x.
Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine.
Barnes N, Ge J, Jones W, Naylor R, Rudd J
Br J Cancer. 1990; 62(5):862-4.
PMID: 2173945
PMC: 1971539.
DOI: 10.1038/bjc.1990.395.
